A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

509

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Bimekizumab
OTHER: Placebo

Sponsor

UCB Biopharma SRL